Related Experiment Video

Updated: May 7, 2026

Simultaneous Measurement of HDAC1 and HDAC6 Activity in HeLa Cells Using UHPLC-MS
09:20

Simultaneous Measurement of HDAC1 and HDAC6 Activity in HeLa Cells Using UHPLC-MS

Published on: August 10, 2017

The development and potential clinical utility of biomarkers for HDAC inhibitors

Baowen Shi1, Wenfang Xu

  • 1Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Shandong University, Ji'nan, Shandong, China.

Drug Discoveries & Therapeutics
|September 28, 2013
PubMed

Insights

Histone deactylase (HDAC) inhibitors are crucial in cancer treatment. Understanding their mechanism of action through biomarkers can improve drug development and predict patient response, reducing failure rates in clinical trials.

Area of Science:

  • Oncology
  • Pharmacology
  • Biomarker Discovery

Background:

  • Drug discovery is a lengthy and expensive process with high failure rates, particularly in clinical trials.
  • Biomarkers are increasingly utilized to predict treatment response and evaluate drug efficacy in oncology.
  • Histone deactylase (HDAC) inhibitors represent a promising class of anti-cancer drugs, but their precise cellular mechanisms require further elucidation.

Purpose of the Study:

  • To explore the development of biomarkers for histone deactylase (HDAC) inhibitors.
  • To investigate the potential clinical utility of these HDAC inhibitor biomarkers.
  • To enhance the understanding of HDAC inhibitors' cellular mechanisms of action.

Main Methods:

  • Review of existing literature on HDAC inhibitors and biomarker development.
  • Analysis of data related to drug discovery and clinical trial outcomes.
  • Focus on identifying and validating biomarkers associated with HDAC inhibitor activity.

Main Results:

  • Elucidation of the cellular mechanism of action for HDAC inhibitors.
  • Identification of specific biomarkers predictive of response to HDAC inhibitors.
  • Demonstration of the potential for biomarkers to improve drug development efficiency.

Conclusions:

  • Biomarkers are essential for understanding HDAC inhibitor mechanisms and predicting treatment outcomes.
  • Development and application of HDAC inhibitor biomarkers can significantly improve the success rate of drug discovery.
  • Further clinical utility studies are warranted to validate these biomarkers in patient populations.

More Related Videos

Assays for Validating Histone Acetyltransferase Inhibitors09:11

Assays for Validating Histone Acetyltransferase Inhibitors

Published on: August 6, 2020

Examination of Proteins Bound to Nascent DNA in Mammalian Cells Using BrdU-ChIP-Slot-Western Technique09:14

Examination of Proteins Bound to Nascent DNA in Mammalian Cells Using BrdU-ChIP-Slot-Western Technique

Published on: January 14, 2016

Related Concept Videos

Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Huntington Disease l: Introduction01:21

Huntington Disease l: Introduction

Huntington disease or HD is a progressive, fatal neurodegenerative disorder inherited in an autosomal dominant pattern.PathophysiologyIt is caused by expansion of the CAG trinucleotide repeat in the HTT gene on chromosome 4 (4p16.3), producing an abnormal huntingtin protein with an expanded polyglutamine tract. This misfolded protein disrupts cellular function, leading to neuronal death. Normal alleles have ≤26 repeats, 27–35 are intermediate (risk of expansion), 36–39 show reduced penetrance,...